We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fast-Growing European Market for Molecular Diagnostics

By HospiMedica staff writers
Posted on 08 Sep 2006
Molecular diagnostics is one of the fastest growing areas in the European in vitro diagnostics (IVD) market. More...
To maximize the tremendous growth potential of molecular diagnostics, market participants will need to effectively communicate with healthcare providers and keep them updated on technologic advancements as well as the availability of new tests.

According to a new report from Frost & Sullivan (Palo Alto, CA, USA), the European molecular diagnostics market earned revenues of U.S.$517.5 million in 2005, which are estimated to reach $987.5 million in 2012.

"Early diagnosis and technological superiority over immunoassays are the key factors driving the wider adoption of molecular tests in Europe,” noted AK Arun, a research associate at Frost & Sullivan. "An emphasis on enhanced patient care, better therapeutic options, and population-screening programs are boosting the uptake of tests.”

Automated and integrated molecular diagnostic solutions are improving assay performance by decreasing the complexity involved in a molecular test. Despite the relatively high price of molecular tests, the inherent benefits, including reduced labor requirements and low cost per assay, will support their adoption.

”However, market success will depend to a large extent on effective communication,” cautioned Mr. Arun. "Manufacturers will need to communicate the value of their technologies to healthcare regulators, payers, providers and patients.”

Many molecular diagnostic assays are novel in the information they provide to the physician and the patient. Therefore, creating awareness and educating healthcare providers and patients alike will be necessary both for the success of the assay and also to qualify for reimbursement.

"Molecular diagnostics companies must conduct awareness programs aimed at educating physicians on developments in pharmacogenomics and cancer diagnosis, in addition to infectious disease screening,” advised Mr. Arun. "As recommendations by physicians and cancer association groups strongly influence the adoption of molecular tests, such awareness programs will be critical to the success of manufacturers.”



Related Links:
Frost & Sullivan

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical-Grade Display
HL2316SHTB
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.